IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Understanding And Addressing Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Holistic Approach For Improved Patient Care

Author: Mrs.D.Asha –Assistant Professor , KMCT College of Nursing, Kozhikode.

Co-Author: Dr. Manjula S Professor , KMCT College of Nursing, Kozhikode.

Abstract:

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a prevalent and often debilitating side effect of chemotherapeutic agents such as taxanes and platinum compounds. Characterized by sensory, motor, and autonomic dysfunction, CIPN significantly impacts patients' quality of life and can lead to dose modifications or discontinuation of cancer treatment. Recent studies have elucidated the pathophysiology of CIPN, highlighting mechanisms such as DNA crosslinking, impaired calcium homeostasis, mitochondrial damage, increased reactive oxygen species, pro-inflammatory cascades, axonal degeneration, and programmed cell death. Despite these insights, effective pharmacological treatments remain limited. Emerging non-pharmacological interventions, including acupuncture and exercise, have shown promise in alleviating CIPN symptoms. A phase 3 randomized controlled trial demonstrated that acupuncture, when combined with standard care, significantly improved sensory scores and quality of life in breast cancer patients with CIPN. Additionally, a systematic review and network meta-analysis indicated that exercise interventions can effectively reduce CIPN symptoms and enhance quality of life. These findings suggest that integrating non-pharmacological therapies may offer valuable options for managing CIPN, warranting further investigation and consideration in clinical practice.

Keywords: Neuropathy, chemotherapy,CIPN

Introduction:

Cancer treatment has significantly evolved over the past decades, improving survival rates and offering new hope to millions of patients worldwide. However, along with these advancements come numerous side effects that can impact patients quality of life. Among them, one particularly concerning issue is the damage to the peripheral nervous system caused by chemotherapy. This condition, known as chemotherapy-induced peripheral nephropathy (CIPN),is a common and often persistent side effects associated with several widely used chemotherapeutic agents.

Background and Significance

Chemotherapy drugs, such as paclitaxel, cisplatin, and vincristine, are frequently used in the treatment of various cancers. While these drugs are effective in targeting cancer cells, they can also cause damage to peripheral nerves, leading to CIPN. The neuropathy may occur within weeks or months of starting chemotherapy, and its severity can vary widely among patients. The impact of CIPN is not just physical but also psychological and emotional, affecting daily functioning, mental health, and overall well-being.2024-25 Statistics says that:

- Globally, CIPN affects approximately 30% to 40% of patients undergoing chemotherapy .
- Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment, with prevalence rates ranging from 68% within the first month of treatment to 30% at 6 months or more. While CIPN symptoms often improve with time, many patients experience persistent symptoms even after treatment completion.



Definition:

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition where the peripheral nerves are damaged by chemotherapeutic agents. This damage can lead to various symptoms, including pain, numbness, tingling, and a loss of sensation in the extremities, often affecting the hands and feet. CIPN can also impact motor and autonomic functions, further impacting a person's quality of life.

Etiopatholgy:



Pathophysiology:



Signs & symptoms:

Sensory Symptoms

- Tingling or "pins and needles" (paresthesia)
- Numbness in the hands, feet, fingers, or toes
- Burning sensations
- Sharp, stabbing, or electric-shock-like pain
- Increased sensitivity to touch (allodynia)
- Loss of position sense (proprioception), leading to clumsiness

Motor Symptoms

- Muscle weakness
- Difficulty with fine motor skills (e.g., buttoning shirts)
- Cramping or twitching
- Loss of coordination or balance
- Foot drop in severe cases

Autonomic Symptoms (less common but possible)

- Constipation
- Urinary retention or incontinence
- Blood pressure fluctuations (e.g., orthostatic hypotension)
- Sexual dysfunction
- Sweating abnormalities

Functional Impairments

- Difficulty walking
- Trouble with daily activities (e.g., writing, using utensils)
- Increased risk of falls and injuries



Grade:

GRADE	(CIPN - Sensory)	(CIPN - Motor)
0	No symptoms.	No symptoms.
1	Asymptomatic; loss of deep tendon reflexes or paresthesia (e.g., tingling) without functional impairment.	Asymptomatic; weakness on exam without functional impairment.
2	Moderate symptoms; limiting instrumental activities of daily living (e.g., preparing meals, using phone, shopping).	Mild to moderate weakness; limiting instrumental ADLs.
3	Severe symptoms; limiting self-care activities of daily living (e.g., bathing, dressing).	Severe weakness; limiting self-care ADLs.
4	Life-threatening consequences; urgent intervention indicated.	Life-threatening consequences; urgent intervention indicated (e.g., respiratory compromise).
5	Death. (Very rare from CIPN directly.)	Death.

Diagnostic studies:

Nerve Conduction Studies (NCS)

- Measures speed and strength of electrical signals in nerves
- Detects large fiber neuropathy

Electromyography (EMG):

- Evaluates electrical activity in muscles
- Identifies motor nerve involvement

Quantitative Sensory Testing (QST)

- Tests thresholds for vibration, temperature, and pain
- Detects early sensory deficits

Skin Biopsy

- Assesses intraepidermal nerve fiber density
- Used for diagnosing small fiber neuropathy

Laboratory Investigations (to rule out other causes)

- Vitamin B12, Folic acid, HbA1c (diabetes), TSH
- Liver and kidney function tests

MRI: Rule out spinal cord compression, nerve root damage, or brain lesions that may mimic neuropathy.

CT: It may detect bony or mass lesions compressing nerves.

PET: Assess metabolic activity; used mainly in cancer staging or recurrence.

MANAGMENTS:

- ✓ First-Line Agents (with strongest evidence)- Duloxetine
- ✓ Second line Agents - Gabapentin ,Pregabalin
- ✓ Tricyclic Antidepressants - Amitriptyline, Nortriptyline)
- ✓ Adjunctive Agents -
- ✓ Topical Agents -Lidocaine patch,Capsaicin 8% patch
- ✓ Opioids - Ketamine
- ✓ Vitamin Supplements (as adjuncts)- Vitamin B12, B6, E, alpha-lipoic acid



NON PHARMACOLOGICAL THERAPY

- ➢ Exercise and Physical Therapy
- ➢ Acupuncture
- ➢ Cryotherapy (Cold Therapy)
- ➢ Scrambler Therapy – A non-invasive neuro modulation treatment using electrical stimulation. {To reduce chronic neuropathic pain (including CIPN).}
- ➢ Cognitive Behavioural Therapy (CBT)
- ➢ Massage Therapy & Reflexology
- ➢ Mind-Body Therapies
- ➢ Transcutaneous Electrical Nerve Stimulation (TENS)

Complications:

- ❖ Sensory Impairment
- ❖ Motor Dysfunction
- ❖ Gait and Balance Disorders
- ❖ Chronic Pain
- ❖ Autonomic Nervous System Involvement (in rare cases)

Nursing Managments:

- ❖ Neurological Assessment: numbness**,** tingling**,** burning pain**,** sensitivity to cold**, or** muscle weakness**.**
- ❖ Functional Assessment: Gait, balance, fine motor skills, and ability to perform daily activities (e.g., buttoning clothes, writing).
- ❖ Teach proper foot care, especially for diabetic or high-risk patients and fine motor skills.

- ❖ Ensure a safe home environment (good lighting, remove rugs/clutter).
- ❖ Use warm (not hot) water to prevent burns.
- ❖ Avoid tight footwear and prolonged standing.
- ❖ Address anxiety, depression, or frustration due to functional limitations.
- ❖ Provide emotional support and counseling referrals as needed.
- ❖ Ensure adequate intake of B-complex vitamins (especially B12), folate, and antioxidants (under medical supervision).
- ❖ Report any new or worsening symptoms immediately.
- ❖ Practice good foot and hand care (e.g., inspect skin daily, wear protective footwear).

Conclusion:

CIPN is a clinically significant and often persistent complication of chemotherapy that requires multidisciplinary management to balance effective cancer treatment with minimizing neurological harm. Ongoing research aims to develop better preventive and therapeutic strategies to improve outcomes for affected patients.

References:

- Website: https://www.asco.org
- Website: https://www.ons.org
- Website: https://www.cancer.gov
- Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., ... & Loprinzi, C. (2020). Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *Journal of Clinical Oncology*, 38(28), 3325–3348. https://doi.org/10.1200/JCO.20.01399
- Textbook of Peripheral Neuropathy-Editor: Peter D. Donofrio,Publisher: Demos Medical Publishing